The efficacy of Baricitinib plus corticosteroids, along with transcriptomic studies of IFN-I and the discovery of anti-MDA5 AABs in serum from COVID-19 patients, confirms that SARS-CoV-2 can trigger HI in genetically predisposed patients, which can evolve into autoimmune disorders such as MDA5+ DM (20). The gene discussed is IFIH1; the disease is COVID-19.